FDA Panel Endorses New Alzheimer’s Drug After Accelerated Approval
The newest Alzheimer’s drug is on its way for full regulatory approval after a U.S. Food and Drug Administration (FDA) advisory panel voted that the drug was beneficial in slowing cognitive decline. The drug is expected to be fully approved by July 6, 2023.1 In clinical trials the drug, known as lecanemab, demonstrated a 27 […]
Pfizer COVID Shot Linked to Death of Woman in Minnesota
An 82-year-old woman died in a hospital in Twin Cities, Minnesota on June 2, 2022, 16 days after receiving a second booster dose of Pfizer/BioNTech’s Comirnaty messenger RNA (mRNA) COVID-19 shot. Described by one of her two daughters, Leanne Goth, as a “vital, energetic person,” Darlene Carlson was vaccinated on May 17 and within five […]
Research Linked to Leading Cause of Alzheimer’s Disease May Have Been Fabricated
For nearly two decades, Alzheimer’s disease research, research funding, and prescribed drugs have been centered around a 2006 research paper hypothesizing that the cognitive decline causing the debilitating disease is due to buildup in the brain of a protein called the amyloid beta (Aβ) protein. But a recent investigation is questioning whether the data in […]
